LENSAR (LNSR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Q1 2026 revenue was $13.4 million, down 5% year-over-year, primarily due to decreased system sales amid market uncertainty from a terminated acquisition, while net income reached $36.3 million, reversing a $27.3 million loss in Q1 2025, mainly from a $23.9 million gain in warrant liabilities and $10 million in acquisition-related income from a terminated merger deposit.
Recurring revenue reached $12.6 million, up 9% year-over-year and now comprises 94% of total revenue, reflecting strong performance and optimism for future growth as distributor relationships and international sales resume.
The ALLY Robotic Cataract Laser System continues to drive growth, with expanded regulatory clearances in the US, EU, India, Taiwan, and South Korea, though future growth depends on additional clearances and certifications.
The company operates in a highly competitive and regulated environment, facing ongoing supply chain, inflationary, and tariff pressures impacting margins and capital needs.
Focus shifted from short-term financial metrics to rebuilding momentum, expanding placements, and recurring revenue growth post-merger termination.
Financial highlights
Product revenue was $10.1 million, lease revenue $1.7 million, and service revenue $1.7 million for Q1 2026; system revenue dropped to $800,000 from $2.6 million year-over-year.
Gross margin was $6.4 million (48% of revenue), compared to $7.1 million (50%) in Q1 2025, with gross margin impacted by tariffs and inflation.
Net income was $36.3 million ($1.56 per share), versus a net loss of $27.3 million last year, driven by non-cash gains and acquisition deposit recognition.
Adjusted EBITDA was negative $311,000, down from positive $165,000 in Q1 2025.
Cash, cash equivalents, and investments totaled $13.5 million at quarter end.
Outlook and guidance
Management expects recurring revenue growth as system utilization increases and system placements return to historical levels post-merger uncertainty.
SG&A expenses will increase judiciously as the company rebuilds its workforce and supports growth.
Sufficient liquidity is projected for at least 12 months, but additional capital may be needed for expansion or if macroeconomic pressures persist.
The company aims to return to its pre-merger growth trajectory in system placements.
Latest events from LENSAR
- Robotic laser system accelerates growth, efficiency, and outcomes in cataract surgery.LNSR
Corporate presentation15 May 2026 - Recurring revenue rose 15% in 2025, with ALLY installations up 48% and net loss sharply reduced.LNSR
Q4 202531 Mar 2026 - Record Q2 revenue and ALLY placements, global expansion, and break-even adjusted EBITDA.LNSR
Q2 20242 Feb 2026 - ALLY's AI-powered laser system drives efficiency, superior outcomes, and rapid global expansion.LNSR
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Q3 revenue up 38% to $13.5M, with ALLY growth and ongoing supply chain risks.LNSR
Q3 202416 Jan 2026 - Record revenue and ALLY placements in 2024 set up for faster growth and profitability in 2025.LNSR
Q4 202426 Dec 2025 - Stockholders to vote on a merger with $14.00 cash per share plus $2.75 CVR; Board recommends approval.LNSR
Proxy Filing2 Dec 2025 - Shareholders to vote on merger with Alcon, offering $14.00 per share plus $2.75 CVR.LNSR
Proxy Filing2 Dec 2025 - Shareholders to receive $14.00 per share plus a $2.75 CVR in a board-approved merger.LNSR
Proxy Filing2 Dec 2025